The most common serious TEAEs with ruxolitinib versus placebo were pneumonia (4% [3/77]/6% [5/87] vs 9% [4/45]) and alanine aminotransferase increased (4% [3/77]/1% [1/87] vs 2% [1/45]) (Table 3). The gene discussed is GPT; the disease is susceptibility to pneumonia measurement.